Optimalization of Nephroprotection Using Agents Inhibiting Renin-Angiotensin-Aldosterone System
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00528385|
Recruitment Status : Completed
First Posted : September 12, 2007
Last Update Posted : September 12, 2007
|Condition or disease||Intervention/treatment||Phase|
|Chronic Kidney Disease Proteinuria||Drug: Spironolactone (Spironol) 25 mg||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Influence of Adding Aldosterone Receptor Blocker to Dual Renin-Angiotensin-Aldosterone System Blockade on Proteinuria|
|Study Start Date :||March 2005|
- Drug: Spironolactone (Spironol) 25 mg
In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
- Investigate the antiproteinuric effect of adding aldosterone antagonist, spironolactone to the combination therapy with angiotensin converting enzyme inhibitor and AT-1 receptor blocker in maximal recommended doses.
- Investigate the effect of the study intervention on urine excretion of N-acetyl-β-D-glucosaminidase, alfa1-microglobulin and amino-terminal propeptide of type III procollagen.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00528385
|Principal Investigator:||Boleslaw Rutkowski, MD, PhD||Department of Nephrology Transplantology and Internal Medicine. Medical University of Gdansk.|